Intellia Therapeutics (NTLA) Stock Forecast & Price Target

$14.07 +0.95 (+7.24%)

(As of 12:00 PM ET)

Intellia Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
6

Buy
12

Based on 18 Wall Street analysts who have issued ratings for Intellia Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 6 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for NTLA.

Consensus Price Target

$54.94
290.46% Upside

According to the 18 analysts' twelve-month price targets for Intellia Therapeutics, the average price target is $54.94. The highest price target for NTLA is $120.00, while the lowest price target for NTLA is $14.00. The average price target represents a forecasted upside of 290.46% from the current price of $14.07.

Get the Latest News and Ratings for NTLA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Intellia Therapeutics and its competitors.

NTLA Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)	17 Buy rating(s)
Hold	6 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$54.94	$61.77	$61.58	$77.70
Forecasted Upside	290.46% Upside	193.02% Upside	160.62% Upside	156.77% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

NTLA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NTLA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Intellia Therapeutics Stock vs. The Competition

Type	Intellia Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.72	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	318.73% Upside	26,931.54% Upside	9.83% Upside
News Sentiment Rating	Positive News See Recent NTLA News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/19/2024	Canaccord Genuity Group 1 of 5 stars		Reiterated Rating	Buy ➝ Buy	$90.00 ➝ $90.00	+536.94%
11/18/2024	Wells Fargo & Company 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$80.00 ➝ $70.00	+399.64%
11/18/2024	Wedbush 4 of 5 stars		Reiterated Rating	Neutral ➝ Neutral	$14.00 ➝ $14.00	-0.21%
11/18/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral	$14.00	-0.21%
11/18/2024	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$88.00 ➝ $91.00	+544.02%
11/11/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$70.00 ➝ $60.00	+249.85%
Get the Latest News and Ratings for NTLA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
11/8/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$76.00 ➝ $55.00	+232.73%
10/25/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$25.00 ➝ $19.00	+19.12%
10/25/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$31.00 ➝ $20.00	+22.10%
10/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$24.00 ➝ $18.00	+13.56%
9/19/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$54.00 ➝ $54.00	+133.26%
9/11/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$80.00 ➝ $64.00	+218.09%
8/12/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$61.00 ➝ $55.00	+158.95%
8/9/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Bayko Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$65.00 ➝ $65.00	+156.11%
6/24/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$120.00 ➝ $120.00	+379.42%
5/10/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$62.00 ➝ $70.00	+186.77%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform
11/13/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$90.00 ➝ $85.00	+266.54%
11/10/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$78.00 ➝ $57.00	+136.22%
6/13/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$89.00 ➝ $91.00	+106.77%
3/21/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$54.00	+41.10%
2/24/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$123.00 ➝ $116.00	+206.31%
2/24/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$88.00 ➝ $76.00	+100.69%
1/23/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$86.00 ➝ $84.00	+134.11%
1/19/2023	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:25 PM ET.

NTLA Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Intellia Therapeutics is $54.94, with a high forecast of $120.00 and a low forecast of $14.00.
: 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 6 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NTLA shares.
: According to analysts, Intellia Therapeutics's stock has a predicted upside of 290.46% based on their 12-month stock forecasts.
: Intellia Therapeutics has been rated by research analysts at Barclays, Canaccord Genuity Group, Chardan Capital, Citigroup, Oppenheimer, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, Wedbush, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Intellia Therapeutics less than other "medical" companies. The consensus rating score for Intellia Therapeutics is 2.72 while the average consensus rating score for "medical" companies is 2.80. Learn more on how NTLA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

This page (NASDAQ:NTLA) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intellia Therapeutics (NTLA) Stock Forecast & Price Target